Ohmeda And Gensia In Anesthesia-Related Deal
Gensia Laboratories, part of Gensia Inc, is to manufacture a number of generic injectables in conjunction with Ohmeda Pharmaceutical Products Division. The products will be available in the USA under the Ohmeda label as part of the company's expanding portfolio of products for the operating room and intensive care unit.
The firms say that the agreement was spurred by growing customer needs for a comprehensive offering of anesthesia-related products and services. "The agreement with Gensia means that Ohmeda can offer a comprehensive anesthesia package to customers far more quickly and cost-effectively," said Ohmeda PPD president Paul Thomas. "Gensia's existing capabilities give us, in effect, a 'virtual' sterile manufacturing division, permitting us to produce generic injectables with minimal startup time and cost."
Ohmeda is the health care business of the UK-based BOC group. Ohmeda employs around 5,300 staff in 30 countries and has annual revenues of around $850 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze